Payment overview · 2025
General Payments
$2,119.82
100 reported records · 21 companies
Healthcare provider profile · identity verified
Hadia Ashraf, MD
Allopathic & Osteopathic Physicians|Family Medicine · HEMET, CA · NPI 1699702142
Verified facts
What the public records show
CMS Open Payments records show Hadia Ashraf, MD received $2,119.82 in general payments during 2025 across 100 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Prolia, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $361.03 | 17.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $211.54 | 10.0% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $211.40 | 10.0% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $208.11 | 9.8% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $205.87 | 9.7% | 15 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $159.90 | 7.5% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $117.49 | 5.5% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $90.99 | 4.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $83.83 | 4.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.60 | 3.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.32 | 3.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.20 | 2.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.57 | 2.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.92 | 2.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.70 | 1.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.31 | 1.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $29.60 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.55 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.91 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.34 | 0.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.64 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,119.82 | 100 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $247.74 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $233.92 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $209.47 | 12 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $208.11 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $207.61 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $205.87 | 15 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $167.74 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $119.26 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $93.28 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $90.99 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $83.83 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.81 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.81 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.30 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.20 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.20 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.21 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.21 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $46.92 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.70 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.13 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $29.60 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 95 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 162 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 178 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 61 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 269 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
100 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
61 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
269 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
178 | 27 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 728 | 198 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 702 | 216 |
| Atorvastatin Calcium | Atorvastatin Calcium | 602 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 148 |
| Losartan Potassium | Losartan Potassium | 589 | 186 |
| Metformin Hcl | Metformin Hcl | 567 | 167 |
| Gabapentin | Gabapentin | 497 | 141 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 397 | 51 |
| Omeprazole | Omeprazole | 370 | 109 |
| Lisinopril | Lisinopril | 343 | 93 |
| Escitalopram Oxalate | Escitalopram Oxalate | 320 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 82 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 269 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 218 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 63 |
| Meloxicam | Meloxicam | 215 | 63 |
| Simvastatin | Simvastatin | 204 | 59 |
| Trazodone Hcl | Trazodone Hcl | 203 | 59 |
| Tramadol Hcl | Tramadol Hcl | 202 | 46 |
| Furosemide | Furosemide | 181 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 179 | 38 |
| Ibuprofen | Ibuprofen | 178 | 64 |
| Ozempic | Semaglutide | 178 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 174 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 170 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 168 | 49 |
| Azithromycin | Azithromycin | 167 | 119 |
| Jardiance | Empagliflozin | 162 | 49 |
| Donepezil Hcl | Donepezil Hcl | 160 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 156 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 20 |
| Famotidine | Famotidine | 146 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 146 | 32 |
| Carvedilol | Carvedilol | 140 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 40 |
| Alprazolam | Alprazolam | 115 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 30 |
| Benazepril Hcl | Benazepril Hcl | 111 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 111 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 84 |
| Potassium Chloride | Potassium Chloride | 108 | 37 |
| Linzess | Linaclotide | 100 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 97 | 58 |
| Farxiga | Dapagliflozin Propanediol | 95 | 35 |
| Buspirone Hcl | Buspirone Hcl | 93 | 30 |
| Allopurinol | Allopurinol | 91 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 19 |
| Eliquis | Apixaban | 86 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 27 |
| Nystatin | Nystatin | 76 | 42 |
| Alendronate Sodium | Alendronate Sodium | 72 | 20 |
| Xarelto | Rivaroxaban | 71 | 16 |
| Glipizide | Glipizide | 68 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 13 |
| Myrbetriq | Mirabegron | 66 | 19 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 64 | 14 |
| Mounjaro | Tirzepatide | 62 | 12 |
| Prolia | Denosumab | 61 | 34 |
| Finasteride | Finasteride | 60 | 13 |
| Memantine Hcl | Memantine Hcl | 60 | 17 |
| Pregabalin | Pregabalin | 57 | 11 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 56 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 14 |
| Januvia | Sitagliptin Phosphate | 55 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 47 |
| Liothyronine Sodium | Liothyronine Sodium | 53 | 16 |
| Propranolol Hcl | Propranolol Hcl | 50 | 14 |
| Clonidine Hcl | Clonidine Hcl | 47 | 20 |
| Sertraline Hcl | Sertraline Hcl | 47 | 15 |
| Fluconazole | Fluconazole | 46 | 34 |
| Baclofen | Baclofen | 45 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | suppressed |
| Lorazepam | Lorazepam | 44 | 14 |
| Cephalexin | Cephalexin | 43 | 38 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Fenofibrate | Fenofibrate | 42 | 12 |
| Temazepam | Temazepam | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Meclizine Hcl | Meclizine Hcl | 39 | 21 |
| Mirtazapine | Mirtazapine | 39 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 18 |
| Naproxen | Naproxen | 39 | 16 |
| Atenolol | Atenolol | 38 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 34 | suppressed |
| Tobramycin | Tobramycin | 34 | 30 |
| Enalapril Maleate | Enalapril Maleate | 33 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 27 | 18 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | 11 |
| Mupirocin | Mupirocin | 25 | 17 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 11 |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Segluromet | Ertugliflozin/Metformin | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Insulin Glargine Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,119.82 · 100 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PROLIA, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error